EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Richard J Zeifman, Anne C Wagner, Candice M Monson, Robin L Carhart-Harris

Journal of Affective Disorders · 2023-08 · 334 · 100-112

DOI: 10.1016/j.jad.2023.04.105 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2023-08. Verfasst von Richard J Zeifman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Toronto Metropolitan University, Toronto, Canada; Centre for Psychedelic Research, Department of Brain Sciences, Faculty of…. Hauptthemen laut MEDLINE: Psilocybin, Major Depressive Disorder. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research, Alexander Mosley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying psilocybin therapy's therapeutic effects. METHOD: Data was used from a double-blind randomized controlled trial that compared psilocybin therapy (two 25 mg psilocybin session plus daily placebo for six weeks) with escitalopram (two 1 mg psilocybin sessions plus 10-20 mg daily escitalopram for six weeks) among individuals with major depressive disorder (N = 59). All participants received psychological support. Experiential avoidance, connectedness, and treatment outcomes were measured at pre-treatment and at a 6 week primary endpoint. Acute psilocybin experiences and psychological insight were also measured. RESULTS: With psilocybin therapy, but not escitalopram, improvements in mental health outcomes (i.e., well-being, depression severity, suicidal ideation, and trait anxiety) occurred via reductions in experiential avoidance. Exploratory analyses suggested that improvements in mental health (except for suicidal ideation) via reduction in experiential avoidance were serially mediated through increases in connectedness. Additionally, experiences of ego dissolution and psychological insight predicted reductions in experiential avoidance following psilocybin therapy. LIMITATIONS: Difficulties inferring temporal causality, maintaining blindness to condition, and reliance upon self-report. CONCLUSIONS: These results provide support for the role of reduced experiential avoidance as a putative mechanism underlying psilocybin therapy's positive therapeutic outcomes. The present findings may help to tailor, refine, and optimize psilocybin therapy and its delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinMajor Depressive DisorderHumansAnxietyAnxiety DisordersTreatment Outcome

Stichwörter der Autor:innen

Experiential avoidanceMajor depressive disorderMechanism of changePsilocybin therapy

Substanzen

Psilocybin

Autor:innen und Institutionen

  • Department of Psychology, Toronto Metropolitan University, Toronto, Canada; Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK; NYU Langone Centre for…
  • Department of Psychology, Toronto Metropolitan University, Toronto, Canada; Remedy Institute, Toronto, Canada.
  • Department of Psychology, Toronto Metropolitan University, Toronto, Canada.
  • Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK; Psychedelics Division, Neuroscape, University of California, San Francisco, USA.

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Alexander Mosley Charitable Trust

Zitieren

APA

Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of Affective Disorders, 334, 100-112. https://doi.org/10.1016/j.jad.2023.04.105

Vancouver

Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of Affective Disorders. 2023;334:100-112. doi:10.1016/j.jad.2023.04.105

BibTeX
@article{Zeifman2023,
  author = {Zeifman, Richard J and Wagner, Anne C and Monson, Candice M and Carhart-Harris, Robin L},
  title = {How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change},
  journal = {Journal of Affective Disorders},
  year = {2023},
  volume = {334},
  pages = {100--112},
  doi = {10.1016/j.jad.2023.04.105}
}
Kostenlos starten →